Spots Global Cancer Trial Database for bosutinib
Every month we try and update this database with for bosutinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis | |
| Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer | NCT00880009 | Breast Cancer | Bosutinib Letrozole Letrozole | 18 Years - | Pfizer | |
| A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer | NCT01025570 | Pancreatic Canc... | Gemcitabine, Bo... | 18 Years - | University of California, San Francisco | |
| Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects | NCT01374139 | Philadelphia Ch... | Bosutinib Bosutinib | 21 Years - 55 Years | Pfizer | |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | NCT02311998 | B Acute Lymphob... Blast Phase Chr... Blasts More Tha... CD22 Positive Philadelphia Ch... Recurrent Chron... Refractory Chro... | Bosutinib Inotuzumab Ozog... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT03128411 | Leukemia, Chron... | Bosutinib | 20 Years - | Pfizer | |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | NCT02311998 | B Acute Lymphob... Blast Phase Chr... Blasts More Tha... CD22 Positive Philadelphia Ch... Recurrent Chron... Refractory Chro... | Bosutinib Inotuzumab Ozog... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands | NCT02546375 | Chronic Myeloid... | Bosutinib | 18 Years - | Pfizer | |
| Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects | NCT00759837 | Breast Cancer Leukemia, Myelo... | Bosutinib | 18 Years - 65 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) | NCT04578847 | Chronic Myeloid... Chronic Myeloid... BCR-ABL Positiv... | Imatinib Nilotinib Dasatinib Bosutinib | 18 Years - | National Research Center for Hematology, Russia | |
| Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | NCT00261846 | Chronic Myeloid... | Bosutinib | 18 Years - | Pfizer | |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia | NCT02782403 | Accelerated Pha... Blast Phase Chr... Chronic Phase P... Philadelphia Ch... | Axitinib Bosutinib Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | NCT05286528 | Chronic Myeloid... | Bosutinib Imatinib Nilotinib Dasatinib Ponatinib | - | Pfizer | |
| Asciminib Roll-over Study | NCT04877522 | Chronic Myeloge... Leukemia, Myelo... | Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib | 18 Years - | Novartis | |
| Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors | NCT00195260 | Neoplasms | bosutinib bosutinib bosutinib bosutinib | 18 Years - | Pfizer | |
| Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy | NCT02638467 | Leukemia Myelogenous Chronic BCR-ABL Positiv... | Bosutinib Bone Marrow Tra... Bone Marrow cel... | 18 Years - 70 Years | University of Milano Bicocca | |
| Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects | NCT01374139 | Philadelphia Ch... | Bosutinib Bosutinib | 21 Years - 55 Years | Pfizer | |
| Safety And Efficacy Of Bosutinib | NCT02501330 | Chronic Myeloge... | Bosutinib | 0 Years - | Pfizer | |
| Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | NCT00261846 | Chronic Myeloid... | Bosutinib | 18 Years - | Pfizer | |
| Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 | NCT01903733 | Chronic Myeloid... | bosutinib | 18 Years - | Pfizer | |
| Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT03128411 | Leukemia, Chron... | Bosutinib | 20 Years - | Pfizer | |
| Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy | NCT02638467 | Leukemia Myelogenous Chronic BCR-ABL Positiv... | Bosutinib Bone Marrow Tra... Bone Marrow cel... | 18 Years - 70 Years | University of Milano Bicocca | |
| Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients | NCT03885830 | CML, Chronic Ph... CML (Chronic My... CML - Philadelp... Chronic Myeloid... Chronic Myeloid... | Bosutinib Dasatinib Imatinib Nilotinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure | NCT02906696 | Blasts Under 15... Blasts Under 15... Blasts Under 30... Blasts Under 30... Chronic Phase C... | Bosutinib Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 | NCT01903733 | Chronic Myeloid... | bosutinib | 18 Years - | Pfizer | |
| Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer | NCT00793546 | Advanced Breast... | Bosutinib exemestane Exemestane | 18 Years - | Pfizer | |
| A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer | NCT01025570 | Pancreatic Canc... | Gemcitabine, Bo... | 18 Years - | University of California, San Francisco | |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | NCT04971226 | Chronic Myeloid... | Imatinib Nilotinib Bosutinib Dasatinib Asciminib | 18 Years - | Novartis | |
| Bosutinib in Elderly Chronic Myeloid Leukemia | NCT02810990 | Chronic Myeloid... | Bosutinib | 60 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors | NCT02228382 | Previously Trea... | Bosutinib | 18 Years - | Pfizer | |
| Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis | NCT03831776 | Chronic Myeloid... | Bosutinib Ropeginterferon | 18 Years - 75 Years | St. Olavs Hospital | |
| A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML | NCT06423911 | Chronic Myeloid... CML CML, Chronic Ph... | olverembatinib Bosutinib | 18 Years - 99 Years | Ascentage Pharma Group Inc. | |
| Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | NCT05286528 | Chronic Myeloid... | Bosutinib Imatinib Nilotinib Dasatinib Ponatinib | - | Pfizer | |
| CML Treated With Bosutinib After Relapse | NCT02445742 | Chronic Myelobl... | Bosutinib | 18 Years - | PETHEMA Foundation | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| Bosutinib in Elderly Chronic Myeloid Leukemia | NCT02810990 | Chronic Myeloid... | Bosutinib | 60 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Bosutinib in Adult Patients With Recurrent Glioblastoma | NCT01331291 | Glioblastoma | bosutinib | 18 Years - | Massachusetts General Hospital | |
| Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia | NCT02782403 | Accelerated Pha... Blast Phase Chr... Chronic Phase P... Philadelphia Ch... | Axitinib Bosutinib Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Asciminib Roll-over Study | NCT04877522 | Chronic Myeloge... Leukemia, Myelo... | Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib | 18 Years - | Novartis | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis | |
| Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland | NCT05363488 | Myeloid Leukemi... | Bosutinib | 18 Years - | Pfizer | |
| Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer | NCT00793546 | Advanced Breast... | Bosutinib exemestane Exemestane | 18 Years - | Pfizer | |
| Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | NCT00574873 | Chronic Myeloid... | Bosutinib imatinib | 18 Years - | Pfizer | |
| Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure | NCT02906696 | Blasts Under 15... Blasts Under 15... Blasts Under 30... Blasts Under 30... Chronic Phase C... | Bosutinib Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
